Major Breakthrough in Cough Treatment on the Horizon
There’s a major breakthrough in cough treatment on the horizon and it shows promising preliminary results!
Dr. Mandel Sher and Center for Cough are currently enrolling volunteer patients in the clinical trials of AF-219, a new drug that shows promise as a breakthrough in cough treatment. For a limited time, patients have an opportunity to try this promising new drug before it’s available to the general public. Please call Amy today, Center for Cough’s Clinical Research Nurse Coordinator, to learn more about this promising new cough treatment: (727) 393- 8067.
Do you know someone who has been coughing for months, years, or even decades? Has that person seen his or her doctor and tried different cough treatments or cough remedies only to fail and still be coughing? Does that person describe their cough as trying to cough-up something tickling the back of his or her throat? As a concerned family member or friend, are you thinking that this person will never decrease the intensity of his or her cough or get rid of it completely?
Well, thanks to Dr. Mandel Sher and his Cough Specialist physician and scientist colleagues around the world, “Chronic Cough,” a significantly under-diagnosed and under-treated medical problem, is beginning to draw awareness and interest. It is estimated that 10 to 15% of adults suffer from a persistent cough. Yet, in spite of how common “Chronic Cough” is, there is a significant unmet need for cough treatment. But that may be about to change…
AF-219 is a new drug on the horizon to significantly relieve persistent cough. It is in the second phase of clinical trials for FDA approval and preliminary results are very promising! A pill which would be taken by patients twice a day could reduce coughing by 75%. This would be the first new medication in 50 years for this type of cough, which means a real breakthrough in cough treatment. AF-219 targets the nerve endings at the back of the throat, which in people with a persistent cough, may be highly sensitive and easily irritated to produce cough.
Dr. Mandel Sher and Center for Cough are helping to evaluate the effectiveness of AF-219 and are offering cough patients an opportunity to try this new drug before it’s available to the general public. Dr. Sher and his colleague, Dr. Jaclyn Smith from Manchester University in the United Kingdom, presented the preliminary results of this promising new drug at the American Thoracic Society’s International Conference in San Francisco in May 2016.
Volunteers are carefully selected based on meeting specific clinical criteria. Patients do not need to have health insurance to participate. Study medications, labs, examinations, and other medical tests are provided at no cost to eligible patients.
Amy, Clinical Research Nurse Coordinator
Please call Amy, Center for Cough’s Clinical Research Nurse Coordinator, to learn more about this promising new cough treatment: (727) 393- 8067.
